Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 7/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13558701 | 1.00 | ADRA1A (0.35) | ADRA1AADRA1DADRA1BHRH1ADRA2A | |
| SCHEMBL7572187 | 1.00 | ADRA1A (0.35) | ADRA1AADRA1DADRA1BHRH1ADRA2A | |
| SCHEMBL13054359 | 0.91 | ALDH1A1 (0.40) | ADRA1AADRA1DADRA1BHRH1ADRA2A | |
| SCHEMBL7548572 | 0.91 | ALDH1A1 (0.40) | ADRA1AADRA1DADRA1BHRH1ADRA2A | |
| SCHEMBL7546818 | 0.89 | ADRA1A (0.40) | ADRA1AADRA1DADRA1BHRH1ADRA2A | |
| SCHEMBL13054243 | 0.89 | ADRA1A (0.40) | ADRA1AADRA1DADRA1BHRH1ADRA2A | |
| SCHEMBL7552485 | 0.87 | ALDH1A1 (0.35) | ALDH1A1OPRM1CYP2D6 | |
| SCHEMBL13055040 | 0.87 | ALDH1A1 (0.35) | ALDH1A1OPRM1CYP2D6 | |
| SCHEMBL13055245 | 0.87 | ADRA1A (0.38) | ADRA1AADRA1DADRA1BHRH1ADRA2A | |
| SCHEMBL7570231 | 0.87 | ADRA1A (0.38) | ADRA1AADRA1DADRA1BHRH1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | ADRA1A 2811/4885ADRA1D 1104/4885ADRA1B 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.